A New Year, A New Chapter in Hematology

A New Year, A New Chapter in Hematology

As we step into 2025, we reflect on the incredible progress made in hematology and set our sights on the breakthroughs to come. This heartfelt message celebrates the dedication of our doctors, researchers, and patients who inspire hope and innovation every day. Let’s work hand in hand to bring new solutions, brighter outcomes, and life-changing treatments to patients worldwide. Together, we can push the boundaries of medicine and create miracles in hematology. Watch this inspiring New Year message as we welcome a year of health, happiness, and progress. Let’s embrace 2025 with hope and determination!
93 Research Achievements of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences Were Showcased at the 66th ASH

93 Research Achievements of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences Were Showcased at the 66th ASH

The 66th Annual Meeting of the American Society of Hematology (ASH), the largest global academic event in the field of hematology, took place from December 7 to 10, 2024, in San Diego, USA. The event brought  together leading researchers and clinicians from around the world to discuss cutting-edge advancements in hematology, innovative therapies, and ongoing clinical trials.Following rigorous peer review, 10 high-quality abstracts from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences were selected for oral presentations, and an additional 83 abstracts were featured in poster sessions.
JITC丨Combination of Autologous Transplantation and CAR-T Cells Enhances Outcomes in Refractory Large B-Cell Lymphoma: Findings from the Team of Professor Dehui Zou and Professor WentingZheng

JITC丨Combination of Autologous Transplantation and CAR-T Cells Enhances Outcomes in Refractory Large B-Cell Lymphoma: Findings from the Team of Professor Dehui Zou and Professor WentingZheng

Chimeric antigen receptor T-cell (CAR-T) therapy is one of the most promising salvage treatments for relapsed/refractory large B-cell lymphoma (r/r LBCL), offering durable remission for about one-third of patients. However, the remaining two-thirds either fail to respond to CAR-T therapy or experience relapse, resulting in poor survival outcomes. This underscores the urgent need to explore methods to enhance the efficacy of CAR-T therapy.
2025 CASH丨Dr. Rong Fu: Interpretation of the PNH China Guidelines

2025 CASH丨Dr. Rong Fu: Interpretation of the PNH China Guidelines

The 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH) was held in Tianjin from January 3 to 5, under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” Top hematology experts from China and abroad were invited to discuss the latest advancements and future trends in hematology.